Boehringer Mannheim Gmbh

Leland Stanford Junior University

Roche Molecular Systems, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-La Roche Ag

Wolf-Dieter Engel

Christoph Seidel

Geoffrey Burns

Dietrich Seidel

Karl-Siegfried Boos

Gerd Haberhausen

Ellen J Baron

Peter Kaspar

Andreas M Kogelnik

Angelika Kurrle-Weittenhiller

Peter Kasper

The present invention is directed to a method for analyzing the presence of a bacterial pathogen in a clinical sample comprising the steps of (i) at least partially isolating nucleic acid from said sample, characterized in that said nucleic acid is selected from a group consisting of either total nucleic acid, total DNA or total RNA, (ii) quantifying the amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen, and (iii) determining whether said amount of nucleic acid comprising a preselected sequence which is specific for said bacterial pathogen exceeds a first predetermined cut off value.

Quantitative test for bacterial pathogens

A process and a reagent for the specific and direct determination of the LDL-fraction in the presence of other serum lipoproteins by adding a polymeric LDL-aggregating agent, followed by direct turbidimetric measurement of the LDL aggregate. Preferred are polymers which have a comb or brush type structure with the side groups having acid character, such as branched alkane sulfonic acids.

Process and reagent for the specific determination of LDL in serum

SLO peptide antigens are described. These peptide antigens are suitable for the determination of SLO antibodies, as immunogens for the production of antibodies against SLO and as vaccines for the production of vaccines against SLO.

Streptolysin O peptide antigens and methods for the determination of

SLO peptide antigens are described. These peptide antigens are suitable for the determination of SLO antibodies, as immunogens for the production of antibodies against SLO.

Growing community of inventors

Feldafing, Germany

Wolf-Dieter Engel